BURLINGTON, MA— Newmark has successfully arranged the sale of Burlington BioCenter, a premier life science facility located at 4 Burlington Woods Drive in Burlington, Massachusetts. The 109,085-square-foot, four-story building was acquired by an undisclosed owner-user.
The transaction was led by Newmark’s Co-Head of U.S. Capital Markets Robert Griffin, alongside Executive Vice Chairman Edward Maher, Vice Chairman Matthew Pullen, Executive Managing Director James Tribble, Senior Managing Director Samantha Hallowell, and Associate Director William Sleeper. Newmark Financial Analyst Grady Zink also provided analytical support.
“Burlington BioCenter stands alone in the Burlington submarket for its turnkey laboratory infrastructure and modern, full-floor buildouts,” said Pullen. “In a region where many life science buildings remain in shell condition, this asset is truly differentiated by its cutting-edge systems and immediate occupancy potential.”
Completed in 2019, with interior laboratory buildouts finalized in 2022, the property features high-performance lab infrastructure, including pH neutralization, backup power, and high-efficiency HVAC systems. Other highlights include a freight elevator, flexible floor plates with interconnecting staircases, and a striking two-story lobby with floor-to-ceiling glass and premium finishes.
As one of the only fully built-out life science properties in the Burlington submarket, Burlington BioCenter offers immediate move-in readiness—an advantage over many competing properties that require substantial tenant improvements. The building’s strategic location near Interstate 95/Route 128 and Route 3 places it in the heart of a growing suburban life science hub, bolstered by a strong labor pool and access to leading academic and research institutions.
